Edwards’ full-year sales guidance remains unchanged for both the total company and each product group. The company continues to expect full-year total company and TAVR sales growth to be in the 10%-13% range on a constant currency basis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS
- Edwards Lifesciences options imply 6.8% move in share price post-earnings
- Edwards says PARTNER 3 data show continued low rates of all-cause mortality
- EW Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Edwards Lifesciences’ EVOQUE system receives CE Mark